TriSalus Life Sciences, Inc. (TLSI)
4.97
-0.17
(-3.31%)
USD |
NASDAQ |
Sep 03, 15:33
TriSalus Life Sciences Profit Margin (Quarterly) : -80.54% for June 30, 2026
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -80.54% |
| March 31, 2026 | 17.29% |
| December 31, 2025 | -73.86% |
| September 30, 2025 | -93.47% |
| June 30, 2025 | -73.91% |
| March 31, 2025 | -113.2% |
| December 31, 2024 | -122.4% |
| September 30, 2024 | -32.64% |
| Date | Value |
|---|---|
| June 30, 2024 | -58.83% |
| March 31, 2024 | -204.5% |
| December 31, 2023 | -623.0% |
| September 30, 2023 | -27.44% |
| June 30, 2023 | -303.0% |
| March 31, 2023 | -277.1% |
| December 31, 2022 | -698.8% |
| September 30, 2022 | -206.3% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 10.23% |
| Alnylam Pharmaceuticals, Inc. | 12.74% |
| Anika Therapeutics, Inc. | 10.15% |
| Savara, Inc. | -- |
| Vericel Corp. | 2.85% |
Profit Margin (Quarterly) Related Metrics
| Return on Assets | -57.22% |
| Return on Invested Capital | -127.7% |
| Gross Profit Margin (Quarterly) | 86.78% |
| Operating Margin (Quarterly) | -86.03% |
| Return on Net Operating Assets | -193.6% |